ATE260254T1 - Omega-cycloalkyl-prostaglandin e2 derivate - Google Patents

Omega-cycloalkyl-prostaglandin e2 derivate

Info

Publication number: ATE260254T1
Authority: AT; Austria
Prior art keywords: prostaglandin; omega; cycloalkyl; derivatives; formula
Prior art date: 1997-12-25

Application number

AT98961522T

Other languages

English (en)

Inventor

Kousuke Tani

Shuichi Ohuchida

Original Assignee

Ono Pharmaceutical Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-12-25

Filing date

1998-12-24

Publication date

2004-03-15

1998-12-24 Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co

2004-03-15 Application granted granted Critical

2004-03-15 Publication of ATE260254T1 publication Critical patent/ATE260254T1/de

Links

208000023275 Autoimmune disease Diseases 0.000 abstract 1
229920000858 Cyclodextrin Polymers 0.000 abstract 1
208000010412 Glaucoma Diseases 0.000 abstract 1
206010067125 Liver injury Diseases 0.000 abstract 1
208000005107 Premature Birth Diseases 0.000 abstract 1
206010036590 Premature baby Diseases 0.000 abstract 1
206010000210 abortion Diseases 0.000 abstract 1
231100000176 abortion Toxicity 0.000 abstract 1
208000006673 asthma Diseases 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
231100000234 hepatic damage Toxicity 0.000 abstract 1
208000026278 immune system disease Diseases 0.000 abstract 1
230000008818 liver damage Effects 0.000 abstract 1
230000016273 neuron death Effects 0.000 abstract 1
201000001119 neuropathy Diseases 0.000 abstract 1
230000007823 neuropathy Effects 0.000 abstract 1
231100000252 nontoxic Toxicity 0.000 abstract 1
230000003000 nontoxic effect Effects 0.000 abstract 1
210000000056 organ Anatomy 0.000 abstract 1
230000011164 ossification Effects 0.000 abstract 1
208000033808 peripheral neuropathy Diseases 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
229940002612 prodrug Drugs 0.000 abstract 1
239000000651 prodrug Substances 0.000 abstract 1
210000001525 retina Anatomy 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 abstract 1
238000002054 transplantation Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

AT98961522T 1997-12-25 1998-12-24 Omega-cycloalkyl-prostaglandin e2 derivate ATE260254T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP36624497		1997-12-25
PCT/JP1998/005863 WO1999033794A1 (en)	1997-12-25	1998-12-24	φ-CYCLOALKYL-PROSTAGLANDIN E2 DERIVATIVES

Publications (1)

Publication Number	Publication Date
ATE260254T1 true ATE260254T1 (de)	2004-03-15

Family

ID=18486293

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT98961522T ATE260254T1 (de)	1997-12-25	1998-12-24	Omega-cycloalkyl-prostaglandin e2 derivate

Country Status (7)

Country	Link
US (1)	US6262293B1 (de)
EP (1)	EP1042283B1 (de)
KR (1)	KR20010033538A (de)
AT (1)	ATE260254T1 (de)
DE (1)	DE69821987T2 (de)
ES (1)	ES2216336T3 (de)
WO (1)	WO1999033794A1 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6235780B1 (en) *	1998-07-21	2001-05-22	Ono Pharmaceutical Co., Ltd.	ω-cycloalkyl-prostaglandin E1 derivatives
ATE281432T1 (de)	1999-03-05	2004-11-15	Univ Duke	C-16 ungesätigte fp-selektive prostaglandin analoge
US6894175B1 (en)	1999-08-04	2005-05-17	The Procter & Gamble Company	2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
AU2227401A (en) *	2000-01-05	2001-07-16	Ono Pharmaceutical Co. Ltd.	5-thia-omega-(substituted phenyl)-prostaglandin e alcohols, process for preparing the alcohols and pharmaceutical preparations containing the same as the activeingredient
US20020037914A1 (en)	2000-03-31	2002-03-28	Delong Mitchell Anthony	Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020172693A1 (en)	2000-03-31	2002-11-21	Delong Michell Anthony	Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020013294A1 (en)	2000-03-31	2002-01-31	Delong Mitchell Anthony	Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
JP2002027998A (ja) *	2000-09-29	2002-01-29	Shionogi & Co Ltd	神経細胞変性調節活性の測定方法
US6586462B2 (en)	2000-10-20	2003-07-01	Allergan, Inc.	ω-Cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists
US6376533B1 (en) *	2000-10-20	2002-04-23	Allergan Sales, Inc.	Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists
JP2005521726A (ja) *	2002-03-27	2005-07-21	チャーターハウスセラピューティックスリミテッド	医薬化合物における改良
JP2006021998A (ja) *	2002-07-18	2006-01-26	Ono Pharmaceut Co Ltd	Ｅｐ２アゴニストを有効成分とする月経困難症治療剤
ES2584606T3 (es)	2002-10-10	2016-09-28	Ono Pharmaceutical Co., Ltd.	Microesferas que comprenden ONO-1301
WO2004073591A2 (en) *	2003-02-24	2004-09-02	Bayer Healthcare Ag	Diagnostics and therapeutics for diseases associated with g-protein coupled receptor prostaglandin e2 ep2 (prostaglandin e2 ep2)
ATE394372T1 (de)	2003-03-03	2008-05-15	Serono Lab	G-lactamderivate als prostaglandinagonisten
JP2005511607A (ja) *	2003-07-10	2005-04-28	アラーガン、インコーポレイテッド	ＥＰ２受容体作動剤としてのω−シクロアルキル１７−ヘテロアリールプロスタグランジンＥ２類似体
JP2006528154A (ja)	2003-07-18	2006-12-14	アプライドリサーチシステムズエーアールエスホールディングナームロゼフェンノートシャップ	プロスタグランジン受容体のモジュレータとしてのヒドラジド誘導体
EP2422814A1 (de)	2003-07-25	2012-02-29	Ono Pharmaceutical Co., Ltd.	Heilmittel für Knorpelerkrankungen
JP4893999B2 (ja)	2004-10-22	2012-03-07	小野薬品工業株式会社	吸入用医薬組成物
AR053710A1 (es) *	2005-04-11	2007-05-16	Xenon Pharmaceuticals Inc	Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
AR056968A1 (es) *	2005-04-11	2007-11-07	Xenon Pharmaceuticals Inc	Compuestos espiro-oxindol y composiciones farmacéuticas
RU2420316C2 (ru)	2005-06-03	2011-06-10	Оно Фармасьютикал Ко., Лтд.	Агент для регенерации и/или защиты нервов
LT1976828T (lt)	2005-12-29	2017-04-25	Celtaxsys, Inc.	Diamino dariniai, kaip leukotrieno a4 hidrolazės inhibitoriai
US20110294842A9 (en) *	2006-10-12	2011-12-01	Xenon Pharmaceuticals Inc.	Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain
WO2008060789A2 (en)	2006-10-12	2008-05-22	Xenon Pharmaceuticals Inc.	Use of spiro-oxindole compounds as therapeutic agents
CA2741024A1 (en) *	2008-10-17	2010-04-22	Xenon Pharmaceuticals Inc.	Spiro-oxindole compounds and their use as therapeutic agents
JO3032B1 (ar) *	2008-10-17	2016-09-05	Xenon Pharmaceuticals Inc	مركبات سبيرو – اوكسندول وإستعمالاتها كعوامل علاجية.
AR077252A1 (es)	2009-06-29	2011-08-10	Xenon Pharmaceuticals Inc	Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
CA2768154C (en)	2009-07-13	2018-02-13	Irix Pharmaceuticals	Synthesis of prostanoids
KR20120099429A (ko)	2009-10-14	2012-09-10	제논 파마슈티칼스 인크.	스피로-옥스인돌 화합물의 합성 방법
US20110086899A1 (en) *	2009-10-14	2011-04-14	Xenon Pharmaceuticals Inc.	Pharmaceutical compositions for oral administration
US8299068B2 (en) *	2010-01-29	2012-10-30	Allergan, Inc.	Therapeutically active cyclopentanes
WO2011106729A2 (en)	2010-02-26	2011-09-01	Xenon Pharmaceuticals Inc.	Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
HK1205114A1 (en)	2012-04-12	2015-12-11	Xenon Pharmaceuticals Inc.	Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents
EP2913047B1 (de)	2012-10-29	2019-05-08	Cardio Incorporated	Spezifisches therapeutikum für pulmonale erkrankungen
CA2906035A1 (en)	2013-03-14	2014-09-25	Celtaxsys, Inc.	Inhibitors of leukotriene a4 hydrolase
CN105592851A (zh)	2013-09-30	2016-05-18	帕西昂Api服务公司	利用复分解反应的前列腺素和前列腺素中间体的新合成途径
US9968716B2 (en)	2013-10-15	2018-05-15	Ono Pharmaceutical Co., Ltd.	Drug-eluting stent graft
WO2016127068A1 (en)	2015-02-05	2016-08-11	Teva Pharmaceuticals International Gmbh	Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound
WO2017014315A1 (ja) *	2015-07-23	2017-01-26	小野薬品工業株式会社	Ｅｐ２アゴニスト活性を有する化合物
US10100060B2 (en)	2016-06-16	2018-10-16	Xenon Pharmaceuticals Inc.	Asymmetric synthesis of funapide
US10385007B2 (en)	2016-12-09	2019-08-20	Celtaxsys, Inc.	Monamine and monoamine derivatives as inhibitors of leukotriene A4 hydrolase
AU2017371348B2 (en)	2016-12-09	2022-02-03	Celltaxis, Llc	Inhibitors of leukotriene A4 hydrolase
US10202334B2 (en)	2016-12-09	2019-02-12	Celtaxsys, Inc.	Pendant amines and derivatives as inhibitors of leukotriene A4 hydrolase
WO2023127855A1 (ja) *	2021-12-28	2023-07-06	大内新興化学工業株式会社	シクロペンテノン誘導体およびその製造方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4132738A (en) *	1978-02-23	1979-01-02	Miles Laboratories, Inc.	Preparation of 15-deoxy-16-hydroxyprostaglandins
US4275224A (en)	1978-02-23	1981-06-23	Miles Laboratories, Inc.	15-Deoxy-16-hydroxy prostaglandins

1998
- 1998-12-24 DE DE69821987T patent/DE69821987T2/de not_active Expired - Fee Related
- 1998-12-24 WO PCT/JP1998/005863 patent/WO1999033794A1/en not_active Ceased
- 1998-12-24 ES ES98961522T patent/ES2216336T3/es not_active Expired - Lifetime
- 1998-12-24 US US09/582,348 patent/US6262293B1/en not_active Expired - Fee Related
- 1998-12-24 KR KR1020007007046A patent/KR20010033538A/ko not_active Ceased
- 1998-12-24 EP EP98961522A patent/EP1042283B1/de not_active Expired - Lifetime
- 1998-12-24 AT AT98961522T patent/ATE260254T1/de not_active IP Right Cessation

Also Published As

Publication number	Publication date
US6262293B1 (en)	2001-07-17
WO1999033794A1 (en)	1999-07-08
EP1042283B1 (de)	2004-02-25
DE69821987D1 (de)	2004-04-01
KR20010033538A (ko)	2001-04-25
EP1042283A1 (de)	2000-10-11
DE69821987T2 (de)	2004-12-16
ES2216336T3 (es)	2004-10-16

Legal Events

Date	Code	Title	Description
2004-08-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE260254T1 (de)	2004-03-15	Omega-cycloalkyl-prostaglandin e2 derivate
ATE218544T1 (de)	2002-06-15	Omega-zykloalkyl-prostaglandin e1 derivate
EP0860430A3 (de)	1999-06-23	Omega-Zykloalkyl-Prostaglandin E2 Derivate
CA2413190A1 (en)	2002-01-10	Methods for treating rheumatic diseases using a soluble ctla4 molecule
JO2282B1 (en)	2005-09-12	Oxazole derivatives
BG106867A (en)	2003-02-28	Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory autoimmune and respiratory diseases
LU91928I2 (fr)	2012-03-09	Ipilimumab et ses dérivés pharmaceutiquement acceptables (YERVOY®)
BR9815761A (pt)	2000-12-26	Processo a vácuo para a fabricação de copolìmeros de siloxano-oxialquileno
BR9811099A (pt)	2002-05-14	Inibidores de urocinase
ATE248837T1 (de)	2003-09-15	Chinuclidin-acrylamide
BRPI0412893A (pt)	2006-10-03	composto, composição farmacêutica, uso de um composto, e, métodos de prevenção, tratamento ou melhora de doenças ou condições inflamatórias, ou doenças ou condições oftálmicas, de tratamento ou melhora de cáncer e para a produção de um composto
AU2002314914A1 (en)	2002-12-16	Hydroxy alkyl amine derivatives as beta-secretase inhibitors and their use for the treatment of alzheimer's disease and similar diseases
BR0318278A (pt)	2006-05-23	compostos de éter aminocicloexìlico e usos dos mesmo
WO2003063787A3 (en)	2004-01-22	Non-steroidal analogs of 2-methoxyestradiol
NO20050664L (no)	2005-04-15	2,4 substituerte indoler og anvendelse derav som 5-HT6 modulatorer
NO20050666L (no)	2005-03-11	2,7-substituerte indoler og deres anvendelse som 5-HT6 modulatorer
WO2003072558A3 (en)	2003-12-24	Arylsulfone derivatives
AU2004216182A1 (en)	2004-09-10	Selective non-steroidal glucocorticoid receptor modulators
TR199902257T2 (xx)	1999-12-21	Tetrahidropirido bile�ikleri
NO20014240D0 (no)	2001-08-31	C16-umettede FP-selektive prostaglandinanaloger
PT1109560E (pt)	2004-01-30	Compostos uteis como inidores de aicarft
EP1328511A4 (de)	2005-11-30	Substituierte (e)-styrylbenzylsulfone zur behandlung proliferativer erkrankungen
EP1121932A4 (de)	2001-12-19	Heilmittel für augenerkrankungen
WO2000058328A3 (de)	2001-04-26	Avermectinderivate
BG106078A (en)	2002-05-31	Thio-oxindole derivatives